AstraZeneca Imfinzi/tremelimumab shows survival benefit in lung cancer in 4-year data Finances September 12, 2022 [ad_1] Lisa Maree Williams AstraZeneca (NASDAQ:AZN) stated ~4 years of follow-up knowledge from a part 3 trial advised {that a}…
